Diligence memo · auto-generated · as of July 2, 2026
Remunix, Inc.
Remunix, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Remunix, Inc. operates in Biotechnology, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Remunix, Inc. has raised $16M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2024-02-29.
Most recent recorded round closed around 2024-02-29.
Valuation (modeled)modeled
Provath models Remunix, Inc. at approximately $129M (range $31M–$247M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.77× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (77% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.